Skip to main content
SpringerLink
Log in

Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The coronary artery disease (CAD) is a chronic inflammatory disease caused by atherosclerosis, in which arteries become clogged due to plaque formation, fat accumulation, and various sorts of immune cells. IL-32 is a proinflammatory cytokine, which enhances inflammation through inducing the secretion of different inflammatory cytokines. The main objective of the current study was to assess the serum levels of IL-32 in subjects with obstructive CAD and its relationship with the serum levels of IL-6 and TNF-α. This study was performed on 42 subjects with obstructive CAD and 42 subjects with non-obstructive CAD. The serum levels of TNF-α, IL-6, and IL-32 were measured using the enzyme-linked immunosorbent assay (ELISA). The serum levels of TNF-α, IL-6, and IL-32 were 3.2, 3.48, and 2.7 times higher in obstructive CAD compared to non-obstructive CAD, respectively. Moreover, the serum levels of TNF-α and IL-32 in obstructive CAD with cardiac arterial stenosis in one major vessel were significantly higher than the levels in obstructive CAD with cardiac arterial stenosis in more than one major vessel. ROC curve analysis revealed that the serum levels of TNF-α, IL-6, and IL-32 were good predictors of obstructive CAD. Moreover, multiple logistic regression analyses suggested that the serum levels of TNF-α, IL-6, IL-32, LDL, and ox-LDL were independently related to the presence of obstructive CAD, while serum levels of HDL were not. TNF-α, IL-32, and IL-6 showed an increase in obstructive CAD, and the serum levels of these cytokines showed a satisfactory ability for predicting obstructive CAD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mortality GBD and Causes of Death C (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117–171

    Article  Google Scholar 

  2. Lusis AJ (2000) Atherosclerosis. Nature 407:233–241

    Article  CAS  Google Scholar 

  3. Mohmmad-Rezaei M, Arefnezhad R, Ahmadi R et al (2021) An overview of the innate and adaptive immune system in atherosclerosis. IUBMB Life 73:64–91

    Article  CAS  Google Scholar 

  4. Ouimet M, Barrett TJ, Fisher EA (2019) HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease. Circ Res 124:1505–1518

    Article  CAS  Google Scholar 

  5. Rafiei A, Ferns GA, Ahmadi R et al (2021) Expression levels of miR-27a, miR-329, ABCA1, and ABCG1 genes in peripheral blood mononuclear cells and their correlation with serum levels of oxidative stress and hs-CRP in the patients with coronary artery disease. IUBMB Life 73:223–237

    Article  CAS  Google Scholar 

  6. Jaitin DA, Adlung L, Thaiss CA et al (2019) Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178:686–698

    Article  CAS  Google Scholar 

  7. Libby P, Lichtman AH, Hansson GK (2013) Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38:1092–1104

    Article  CAS  Google Scholar 

  8. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22:131–142

    CAS  PubMed  Google Scholar 

  9. Netea MG, Azam T, Ferwerda G et al (2005) IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 102:16309–16314

    Article  CAS  Google Scholar 

  10. Fadaei R, Bagheri N, Heidarian E et al (2020) Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-alpha and IL-6. Cytokine 125:154832

    Article  CAS  Google Scholar 

  11. Joosten LA, Netea MG, Kim SH et al (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298–3303

    Article  CAS  Google Scholar 

  12. Shioya M, Nishida A, Yagi Y et al (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480–486

    Article  CAS  Google Scholar 

  13. Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:606

    Article  CAS  Google Scholar 

  14. McLaren JE, Michael DR, Ashlin TG, Ramji DP (2011) Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50:331–347

    Article  CAS  Google Scholar 

  15. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC (2016) Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J 37:1723–1732

    Article  CAS  Google Scholar 

  16. Yang Z, Shi L, Xue Y et al (2019) Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. Clin Chim Acta 497:104–109

    Article  CAS  Google Scholar 

  17. Gotsman I, Stabholz A, Planer D et al (2008) Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J 10:494

    PubMed  Google Scholar 

  18. Akita K, Isoda K, Sato-Okabayashi Y et al (2017) An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front Cardiovasc Med 4:84

    Article  Google Scholar 

  19. Babaee M, Chamani E, Ahmadi R et al (2020) The expression levels of miRNAs-27a and 23a in the peripheral blood mononuclear cells (PBMCs) and their correlation with FOXO1 and some inflammatory and anti-inflammatory cytokines in the patients with coronary artery disease (CAD). Life Sci 256:117898

    Article  CAS  Google Scholar 

  20. Damen M, Popa CD, Netea MG, Dinarello CA, Joosten LAB (2017) Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. Atherosclerosis 264:83–91

    Article  CAS  Google Scholar 

  21. Heinhuis B, Popa CD, van Tits BL et al (2013) Towards a role of interleukin-32 in atherosclerosis. Cytokine 64:433–440

    Article  CAS  Google Scholar 

  22. Damen MS, dos Santos JC, Hermsen R et al (2018) Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. Atherosclerosis 271:193–202

    Article  CAS  Google Scholar 

  23. Lei L, Xiong Y, Chen J et al (2009) TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J Lipid Res 50:1057–1067

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Shahrekord University of Medical Sciences financially supported this study with grant number 3118.

Author information

Authors and Affiliations

  1. Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

    Mina Mohammad-Rezaei, Ali Rafiei, Soheila Fattahi, Azadeh Samiei-Sefat & Shohreh Emami

  2. Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

    Reza Ahmadi & Nader Bagheri

  3. Department of Cardiology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

    Arsalan Khaledifar

Authors
  1. Mina Mohammad-Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Reza Ahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Rafiei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arsalan Khaledifar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soheila Fattahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Azadeh Samiei-Sefat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shohreh Emami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nader Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nader Bagheri.

Ethics declarations

Conflict of interest

All authors approved this manuscript. No competing interests declared.

Ethical approval

This study was approved by the ethical board of Shahrekord University of medical sciences with Number: IR.SKUMS.REC.1398.199.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammad-Rezaei, M., Ahmadi, R., Rafiei, A. et al. Serum levels of IL-32 in patients with coronary artery disease and its relationship with the serum levels of IL-6 and TNF-α. Mol Biol Rep 48, 4263–4271 (2021). https://doi.org/10.1007/s11033-021-06441-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06441-7

Keywords

Search

Navigation